Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
232.32
-9.47 (-3.92%)
At close: Apr 28, 2026, 4:00 PM EDT
232.33
+0.01 (0.00%)
After-hours: Apr 28, 2026, 5:27 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Ligand Pharmaceuticals stock have an average target of 249.71, with a low estimate of 220 and a high estimate of 282. The average target predicts an increase of 7.49% from the current stock price of 232.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $235 → $252 | Buy | Maintains | $235 → $252 | +8.47% | Apr 28, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $276 → $282 | Strong Buy | Maintains | $276 → $282 | +21.38% | Apr 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $239 → $243 | Strong Buy | Maintains | $239 → $243 | +4.60% | Apr 14, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $270 → $276 | Strong Buy | Maintains | $270 → $276 | +18.80% | Mar 24, 2026 |
| B of A Securities | B of A Securities | Strong Buy Initiates $244 | Strong Buy | Initiates | $244 | +5.03% | Mar 11, 2026 |
Financial Forecast
Revenue This Year
271.43M
from 268.09M
Increased by 1.25%
Revenue Next Year
324.12M
from 271.43M
Increased by 19.41%
EPS This Year
9.59
from 6.13
Increased by 56.39%
EPS Next Year
11.89
from 9.59
Increased by 23.99%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 291.9M | 360.5M | ||||||
| Avg | 271.4M | 324.1M | ||||||
| Low | 248.2M | 288.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 8.9% | 32.8% | ||||||
| Avg | 1.2% | 19.4% | ||||||
| Low | -7.4% | 6.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 15.12 | 23.40 | |||||
| Avg | 9.59 | 11.89 | |||||
| Low | 8.16 | 8.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 146.6% | 144.1% | |||||
| Avg | 56.4% | 24.0% | |||||
| Low | 33.2% | -7.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.